Biomarkers Consortium

Young research scientists


Lawrence Schwartz

The Vol-PACT project expansion will further advance cutting-edge technologies in the field of image analysis to help track a patient’s response to cancer therapy.

Inflammatory Markers

The FNIH Biomarkers Consortium has launched a project, under its Neuroscience Steering Committee, with the potential to improve diagnosis and the development of targeted therapies for Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD).


The FNIH Biomarkers Consortium has met a critical milestone that could improve clinical trials and accelerate treatment approvals for hospital-acquired bacterial infections.

The Biomarkers Consortium is a public-private biomedical research partnership managed by the Foundation for the National Institutes of Health that endeavors to discover, develop, and seek regulatory approval for biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics.

The Biomarkers Consortium is helping create a new era of precision medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Our goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.

Front Page: